Alkermes Plc Quick Ratio (ALKS) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Alkermes Plc   (NASDAQ: ALKS)

Alkermes Plc 's Quick Ratio

ALKS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.77 a new company low.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Alkermes Plc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1005 to 2023.

Explain Quick Ratio?
How much Cash & cash equivalents ALKS´s has?
What are ALKS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ALKS Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 30.86 % 35.1 % 16.82 % 4.55 % -1.86 %
Y / Y Cash & cash equivalent Change -49.64 % -42.1 % -21.75 % 22.25 % 15.94 %
Quick Ratio MRQ 0.77 0.85 1.08 2.34 2.01
ALKS's Total Ranking # 2023 # 1005 # 728 # 899 # 926
Seq. Current Liabilities Change 10.44 % 10.32 % 14.56 % -6.25 % 14.02 %
Seq. Cash & cash equivalent Change -0.07 % -12.98 % -47.06 % 9.39 % 14.9 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 371
Healthcare Sector # 671
Overall Market # 2023


Quick Ratio Statistics
High Average Low
12.26 2.42 0.77
(Mar 31 2014)   (Jun 30 2026)




Financial Statements
Alkermes Plc 's Current Liabilities $ 662 Millions Visit ALKS's Balance sheet
Alkermes Plc 's Cash & cash equivalent $ 512 Millions Visit ALKS's Balance sheet
Source of ALKS's Sales Visit ALKS's Sales by Geography


Cumulative Alkermes Plc 's Quick Ratio

ALKS's Quick Ratio for the trailling 12 Months

ALKS Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 21.98 % 13.05 % 3.91 % -3.04 % -6.47 %
Y / Y Cash & cash equivalent TTM Growth -23.53 % -5.66 % 9.67 % 13.89 % 8.42 %
Quick Ratio TTM 1.19 1.52 1.83 1.99 1.91
Total Ranking TTM # 3954 # 3810 # 2286 # 2996 # 2775
Seq. Current Liabilities TTM Growth 7.35 % 7.92 % 4.14 % 1.11 % -0.51 %
Seq. Cash & cash equivalent TTM Growth -15.63 % -10.34 % -4.34 % 5.68 % 4.08 %

Quick ratio ranking by company, industry and sector >> Back to ALKS Financial Strength Comparisons >> Go to Compare ALKS Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $662.09 millions, cumulative Quick Ratio decreased to 1.19 below the Alkermes Plc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Alkermes Plc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 3810 to 3954.

Explain Quick Ratio?
How much Cash & cash equivalents ALKS´s has?
What are ALKS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 889
Within the Market # 3954


trailing twelve months Quick Ratio Statistics
High Average Low
5.67 2.24 1.19
(Mar 31 2015)   (Jun 30 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Oragenics Inc   2.12 $ 3.864  Millions$ 1.822  Millions
Pacira Biosciences inc   2.06 $ 251.031  Millions$ 122.011  Millions
Genelux Corporation  2.05 $ 29.870  Millions$ 14.590  Millions
Opko Health Inc   2.01 $ 300.761  Millions$ 149.367  Millions
Corcept Therapeutics Inc  2.00 $ 308.197  Millions$ 153.802  Millions
Clene Inc   2.00 $ 9.700  Millions$ 4.852  Millions
Blue Water Vaccines Inc  2.00 $ 5.942  Millions$ 2.974  Millions
Vertex Pharmaceuticals Inc  1.99 $ 7,852.400  Millions$ 3,937.900  Millions
Metavia Inc   1.99 $ 12.636  Millions$ 6.346  Millions
Connect Biopharma Holdings Limited  1.93 $ 31.500  Millions$ 16.301  Millions
Amarin Corp Plcuk  1.92 $ 314.850  Millions$ 164.195  Millions
Mustang Bio inc   1.91 $ 15.150  Millions$ 7.918  Millions
Therapeuticsmd Inc   1.84 $ 9.189  Millions$ 5.003  Millions
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions
Quoin Pharmaceuticals Ltd   1.63 $ 10.800  Millions$ 6.613  Millions
Mallinckrodt Plc  1.63 $ 1,075.800  Millions$ 660.600  Millions
Macrogenics Inc   1.59 $ 173.305  Millions$ 108.815  Millions
Fibrobiologics Inc   1.59 $ 3.515  Millions$ 2.213  Millions
Sarepta Therapeutics Inc   1.57 $ 788.489  Millions$ 502.908  Millions
Revium Rx.  1.55 $ 1.506  Millions$ 0.971  Millions
Liquidia Corporation  1.50 $ 284.181  Millions$ 189.298  Millions

Date modified: 2026-09-26T06:58:04+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.